SYK and autoimmune thrombocytopenic purpura: However, the experience regarding the SYK inhibitors in the clinical trials for hematological malignancies and the clinical practice for immune thrombocytopenia (ITP) is that the hematological toxicity, i.e., bone marrow suppression, is quite low [5,17,19,21,56,57,58,59].